

ERRATA, OMISSIONS, EXPLANATIONS

In the article “Cancer Drugs and Indications Over the Last Ten Years”, pages 27-35 one additional drug indication should have been included.

The additional listing would therefore have appeared in several places in the article, as follows.

Figure 1, page 27

43. Vorinostat Zolinza

Figure 2, page 29

43. 2009

1 Green code, Full NOC for specified indication June 11, 2009

Figures 3 and 4, page 30

Both graphs would be adjusted to include one additional indication in the year 2009

Figure 5, page 31

In the far right column, for the 5-year period 2005-2009, the number of new cancer drugs should be 21, and the total number for that column should be 60.

Figure 7, page 35

43. Vorinostat (Zolinza)

NOC for cutaneous T-cell lymphoma, 11-June-2009

Throughout the text of the article, all totals of new drugs and new indications would similarly be adjusted upward by this addition.

Page 27, Explanation

Afinitor (everolimus) was announced Dec 14, 2009 by the pharmaceutical company, but the Health Canada NOC date was January 2010, and therefore the product was not included in this article.